Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Amlitelimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Fakultni Nemocnice Bulovka
Dermatovenerologicka klinika
Dolní Chabry, Czechia
Nemocnice AGEL Novy Jicin a.s.
Kozni oddeleni se stacionarem
Nový Jičín, Czechia
CCR Ostrava s.r.o.
Ostrava, Czechia

Sponsor: Sanofi-Aventis Research & Development
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.